I'm giving you the straight scoop. Are you going to be a halt-the-ranger kind of guy and give me insults when I have been right in regards to the stock and the stock price? Have you talked to any of the drug reps? If so, what have they told you? I have another friend who is a lipidologist who noted that his friend in his lipidology clinic had seven people on juxta and only two could tolerate it. No matter what you or I say, earnings coming out tomorrow or within the next couple of days. We'll see, but with Mr. Beer trying to get peds indication approved, scouring the earth all over looking for the hidden population of undiscovered HoF, and with potentially cheaper competitors coming forth this company is in a world of hurt. t
Hope they are reeling by the second anniversary in August 2015 were they are BK. Will be checking on them and hoping for the worst, I mean the best for ISIS shareholders once the Orcan man can remove most of them with a BK public notice. t
What a zero company vicl is. They have been out as long as ISIS and they have a price tag of a buck and change and they are going to zero. The sooner the better as this board can then maybe discuss real ISIS topics rather than vicl sxxx. Hope Pearl acts quickly. Have also asked that anyone who concentrates on prune juice be forever cursed with diarrhea and be forced to move in with women who have the same. t
Hope to get a Jamaican curse on vicl. Will call Uh-Boo Pearl from the mother country to hit vical. Will ask that she spares the dog mouth melanoma drug in case my dog gets that disease. I predict from the curse that the CEO of vicl will say after their next failure in the lab that, "the placebo did better than expected." He never admitted in their last failure but the curse will make him say it this time. t
I don't know if you are messaging me? I'm not a short, but am rather pointing out the value of AKT1 as a target. Have been doing this at this site for over a year. I personally rate AKT1 the number two target for trying to treat CA behind STAT3, followed by PD-1. RNN has an excellent chance of hitting paydirt. My three year target for it is $15. Watching as many competitor that I can and I post any info I find on them to alert people of potential competition. A 360 degree is always best. t
You'd be best advised to follow your own advice and SCRAM back to the vicl board.......it won't happen and that is why I say death to vicl and the sooner the better. t
This isn't an Fxxxing trial in regards to ISIS or some government mandate. They are making huge progress at ISIS and even the RNAi blogger has come around and sees ISIS as the most powerful force in RNA at this time. Within two years they could have drugs on the market that is very valuable. No, the only way to rid the board of this from people like you is for VICL to go BK.......and I'm hoping and watching for that to happen. More so now than ever. Chances are high too. One more failure in the lab and they will be done. The good American workers there can probably latch onto another biotech. The CEO is highly suspect with running a trial and holding back on the info where the placebo patients did better than the treated patients. Short live VICL the sooner they die the better. And I'm waiting for it anxiously. Maybe a big failure by this year and they get delisted from the NSAD.......they are close now, no matter what spin you try and put on......t
I think the tactic of continually bashing ISIS and bringing up VICL over and over and over again on a board that is for ISIS is making ISIS investors who might otherwise look at VICL militant against it like me. KG, what do you think about that? t
I usually wish any American company that is going to employ Americans and trying their best the hope that they do well. However, with this persistent barrage of negative things coming from these VICL cult people I hope and think that VICL will go down the tubes into BK.......the sooner the better. If that would occur they would all disappear, or find a new champion to go up against ISIS in this unwanted contest pushed by them. If that would occur I'd hope for the same fate for that new chosen competitor. Probably won't happen though because those loud crows would have lost further legitimacy amongst biotech investors. Hate to say, but I wish VICL the worst, brought on by these no-nothings that continue to pester this board. If I find out anything negative on VICL it will be broadcast over the VNN ASAP. t
You are a physician and a scientist and you quote a one person numbered study as to your determination in regards to your opinion? I've talked to two pharm reps from the company and both have told me that 5 to 10mg is the dosage that most people are taking.........I would think that those dosages are "discovered" by trial and error in regards to each individual patient. The 23 patient study with all of the superiority so-called was predicated on the average dosage being about 40mg. In the real world it is not any where near that dosage. t
Worked late today and haven't had a chance to look up who did better percentage-wise today. Anxiously await Micro, I mean Macor's report.......who actually did better today ISIS or VICL? Thx in advance, t
Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes
Melanoma Research, 07/25/2014 Clinical Article
Williams B, et al. – Melanoma cell adhesion molecule (MCAM) is upregulated during melanoma progression, and associated with invasion and metastasis. The authors conclude therefore that ETs upregulate MCAM in an Akt and ERK/MEK–dependent, but CREB–independent manner, providing an understanding for possible pharmacologic intervention in progressing melanoma.
Very powerful in the few patients that can tolerate more than 5 to 10mg per day with the restriction being the rapid elevation of liver enzymes AND the diarrhea issue. The remaining issues besides why pay $295K for patients on only 5 to 10mg are the increased risk of developing atrial fibrillation secondary to those elevated liver enzymes, and what about those increases in fatty infiltration of the small intestine? Halt_the_ranger with his vast knowledge has not being able to speak yet:))))))) t
Please take a Rosetta Stone course on how to speak English, or change your name to Senddilxxo(yourself) back to the Antarctic. t
One out of three days that Vicl did a little bit better than ISIS and you have to be a morning rooster about it. Of course you left you that ISIS went up over three points in 48 hrs and that this may relate to profit taking.. VICL is a junk stock, 75% below it's yearly high. It faces a tremendous amount of competition and their products are more dangerous than ISIS IMO. They could cause patients to develop Gillian-Barre Syndrome. Worst yet in their lastest fiasco they may not work at all and may do way worse than placebo. Of course the whole company is guided by arguably the worse CEO in the business last year. Keep on receiving instructions from your biotech equivalent of Mr. Putin and let's continue to talk as the year progresses.........as long as you have the courage to keep on appearing on website that is for ISIS not VICL. I suspect you will because you have Mr. Putin-like training. Looking forward to doing business with you Mr. Putin-like miniature. t
Lpath reports interim data from Phase 2a study for anti-cancer drug, ASONEP; based on encouraging progression-free survival data, co extends the study to a second cohort and considers additional proof-of-concept studies (3.71)
•Co reported interim results in a Phase 2a single-arm, open-label trial where ASONEP is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor/everolimus), with a maximum of three failed treatments in all.
•This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.
You have to be the dumbest liar out there. According to your posts over the last five years you would never own ISIS no matter what.......and to buy it and hold it until 50.....like ya. You keep saying you are loading up on vicl and you live in mom's basement without a job....that's another lie. t
Differential effects of Akt1 signaling on short- versus long-term consequences of myocardial infarction and reperfusion injury
Laboratory Investigation, 07/23/2014 Clinical Article
Ma L, et al. – The data suggest that better understanding of the Akt1/GSK–3 pathway may provide insights for better therapeutic strategies in post–MI tissues.
Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways
Head & Neck, 07/23/2014 Clinical Article
Axelrod MJ, et al. – The authors aim to investigate that synergistic apoptosis in head and neck squamous cell carcinoma (HNSCC) cells by co–inhibition of insulin–like growth factor–1 receptor signaling and compensatory signaling pathways. Combined IGF1R/HER family and IGF1R/Src family inhibition may have therapeutic potential in HNSCC. AKT may be a node of convergence between IGF1R signaling and pathways that compensate for IGF1R inhibition.